Sistemic hires more staff

Moves to larger premises that will become new global hq

Sistemic, a Glasgow, Scotland-based developer of microRNA technologies, has added scientific and bioinformatic staff, and is moving to larger premises near Glasgow, which will also form the company’s new global headquarters.

The company says this will enable it to fulfil current contracts more rapidly, while providing further capacity for newly acquired and future contracts. It will also support the expansion of its key internal r&d programmes in drug toxicology and stem cell characterisation.

The expansion programme will also see the company grow its US commercial operations by developing its Boston location and opening an office in California.

David Mallinson, who previously worked for Merck Sharpe Dohme (MSD), has joined Sistemic as a senior scientist and will lead new projects at the expanded facility.

Max Bylesjo, previously at Almac Group, has joined as senior bioinformatician and will focus on developing Sistemic’s data processing technology.

The new Sistemic headquarters will dedicate 60% of its space to laboratory facilities, equipped with state-of-the-art technology, and 40% as new commercial areas.

You may also like

Regulatory

Scotland launches collaborative approach to cell therapy development

Cell therapy companies to be offered a streamlined process for clinical trials
Research & Development

Sistemic announces companion biomarker programme

Extends miRNA drug discovery toolkit
Research & Development

Sistemic cuts cost of drug discovery

Launches microRNA technology to filter out harmful compounds early in development process
Regulatory

TurboFil debuts latest generation of through-the-tip benchtop syringe filler

TipFil Plus provides precise, aseptic-ready filling and capping for lab and pharmacy applications
Manufacturing

Concentrating recombinant proteins for drug discovery using centrifugal evaporation

Exploring purification, concentration and sample protection in recombinant protein workflows
Research & Development

COVID-19 immunity lowers the risk of a new pandemic

Researchers at the MRC-University of Glasgow Centre for Virus Research have demonstrated that the likelihood of the emergence of a new SARS-type virus pandemic has been significantly reduced by population-wide immunity to SARS-CoV-2
You need to be a subscriber to read this article.
Click here to find out more.
Research & Development

Cytiva enters research partnership with SRTIGET for next-gen genomic medicine

The pair aim to expand the role of lipid nanoparticle technology into gene therapy delivery, including applications in cancer and inherited blood diseases, CNS delivery for neurological disorders where current methods fail and in vivo stem cell modification that could eliminate toxic conditioning regimens
Subscribe now